Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-induced neuropathy

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Peripheral neuropathy is a common dose-limiting toxicity of chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN) causes numerous debilitating symptoms, impairs functional capacity, and results in dose reductions or possible cessation of chemotherapy. Analgesic or neurotropic agents are only modestly effective in treating neuropathic symptoms. Animal and human studies into the pathogenesis of CIPN have demonstrated heterogeneity in the mechanism(s) of nerve injury caused by individual agents, which may partly explain the wide variation in the resultant symptoms. Development of optimal therapeutic measures to treat CIPN requires continued research into the pathophysiologic basis of nerve injury, identification of risk factors for individual patients, development of reproducible and easy-to-use measurement scales, and finally, the performance of appropriately designed clinical trials to evaluate potentially promising agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mielke S, Mross K, Gerds TA, et al.: Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003, 14:785–792.

    Article  PubMed  CAS  Google Scholar 

  2. Seidman AD, Hudis CA, Albanell J, et al.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16:3353–3361.

    PubMed  CAS  Google Scholar 

  3. Gradishar WJ, Tjulandin S, Davidson N, et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794–7803.

    Article  PubMed  CAS  Google Scholar 

  4. Chan S, Friedrichs K, Noel D, et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341–2354.

    PubMed  CAS  Google Scholar 

  5. Pronk LC, Hilkens PH, van den Bent MJ, et al.: Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998, 9:759–764.

    Article  PubMed  CAS  Google Scholar 

  6. McDonald ES, Randon KR, Knight A, et al.: Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005, 18:305–313.

    Article  PubMed  CAS  Google Scholar 

  7. von Schlippe M, Fowler CJ, Harland SJ: Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001, 85:823–826.

    Article  Google Scholar 

  8. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.

    PubMed  Google Scholar 

  9. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343–2351.

    Article  PubMed  CAS  Google Scholar 

  10. Leonard GD, Wright MA, Quinn MG, et al.: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005, 5:116.

    Article  PubMed  CAS  Google Scholar 

  11. Grolleau F, Gamelin L, Boisdron-Celle M, et al.: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293–2297.

    PubMed  CAS  Google Scholar 

  12. Green LS, Donoso JA, Heller-Bettinger IE, et al.: Axonal transport disturbances in vincristine-induced peripheral neuropathy. Ann Neurol 1977, 1:255–262.

    Article  PubMed  CAS  Google Scholar 

  13. Verstappen CC, Koeppen S, Heimans JJ, et al.: Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005, 64:1076–1077.

    PubMed  CAS  Google Scholar 

  14. Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113–3120.

    Article  PubMed  CAS  Google Scholar 

  15. Rajkumar SV, Blood E, Vesole D, et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431–436.

    Article  PubMed  CAS  Google Scholar 

  16. Cheng WY, Jiang YD, Chuang LM, et al.: Quantitative sensory testing and risk factors of diabetic sensory neuropathy. J Neurol 1999, 246:394–398.

    Article  PubMed  CAS  Google Scholar 

  17. Kvarnstrom A, Karlsten R, Quidin H, et al.: The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003, 47:868–877.

    Article  PubMed  CAS  Google Scholar 

  18. Postma TJ, Heimans JJ, Muller MJ, et al.: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739–744.

    Article  PubMed  CAS  Google Scholar 

  19. Berger T, Malayeri R, Doppelbauer A, et al.: Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997, 33:1393–1399.

    Article  PubMed  CAS  Google Scholar 

  20. Forsyth PA, Balmaceda C, Peterson K, et al.: Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997, 35:47–53.

    Article  PubMed  CAS  Google Scholar 

  21. Lecomte T, Landi B, Beaune P, et al.: Glutathione S-trans-ferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006, 12:3050–3056.

    Article  PubMed  CAS  Google Scholar 

  22. Rowbotham MC, Twilling L, Davies PS, et al.: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003, 348:1223–1232.

    Article  PubMed  CAS  Google Scholar 

  23. Gilron I, Bailey JM, Tu D, et al.: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324–1334.

    Article  PubMed  CAS  Google Scholar 

  24. Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  25. Max MB, Lynch SA, Muir J, et al.: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250–1256.

    Article  PubMed  CAS  Google Scholar 

  26. Panerai AE, Monza G, Movilia P, et al.: A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990, 82:34–38.

    Article  PubMed  CAS  Google Scholar 

  27. Hammack JE, Michalak JC, Loprinzi CL, et al.: Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002, 98:195–203.

    Article  PubMed  CAS  Google Scholar 

  28. Luo ZD, Chaplan SR, Higuera ES, et al.: Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001, 21:1868–1875.

    PubMed  CAS  Google Scholar 

  29. Wong GY, Michalak JC, Sloan JA, et al.: A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group Study-N01C3 [abstract]. J Clin Oncol Proc ASCO 2005, 23:8001.

    Google Scholar 

  30. Cheung H, Kamp D, Harris E: An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992, 13:107–112.

    Article  PubMed  CAS  Google Scholar 

  31. Renno SI, Rao RD, Sloan J, et al.: The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3 [abstract]. J Clin Oncol Proc ASCO 2006, 24:8530.

    Google Scholar 

  32. Wilson RH, Lehky T, Thomas RR, et al.: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767–1774.

    Article  PubMed  CAS  Google Scholar 

  33. Argyriou AA, Chroni E, Polychronopoulos P, et al.: Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006, 67:2253–2255.

    Article  PubMed  CAS  Google Scholar 

  34. Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061.

    Article  PubMed  CAS  Google Scholar 

  35. Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003, 21:927–931.

    Article  PubMed  CAS  Google Scholar 

  36. Lynch ME, Clark AJ, Sawynok J, et al.: Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 2005, 103:140–146.

    Article  PubMed  CAS  Google Scholar 

  37. Bianchi R, Buyukakilli B, Brines M, et al.: Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 2004, 101:823–828.

    Article  PubMed  CAS  Google Scholar 

  38. Bohlius J, Langensiepen S, Schwarzer G, et al.: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005, 97:489–498.

    Article  PubMed  CAS  Google Scholar 

  39. Lorusso D, Ferrandina G, Greggi S, et al.: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086–1093.

    Article  PubMed  CAS  Google Scholar 

  40. Cascinu S, Catalano V, Cordella L, et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478–3483.

    Article  PubMed  CAS  Google Scholar 

  41. Vahdat L, Papadopoulos K, Lange D, et al.: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001, 7:1192–1197.

    PubMed  CAS  Google Scholar 

  42. Lin PC, Lee MY, Wang WS, et al.: N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 2006, 14:484–487.

    Article  PubMed  Google Scholar 

  43. Chattopadhyay M, Goss J, Wolfe D, et al.: Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004, 127:929–939.

    Article  PubMed  Google Scholar 

  44. Kirchmair R, Tietz AB, Panagiotou E, et al.: Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: Taxol-and thalidomide-induced injury of vas a nervorum is ameliorated by VEGF. Mol Ther 2007, 15:69–75.

    Article  PubMed  CAS  Google Scholar 

  45. Wong R, Sagar S: Acupuncture treatment for chemotherapy-induced peripheral neuropathy—a case series. Acupunct Med 2006, 24:87–91.

    Article  PubMed  Google Scholar 

  46. http://Cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx. Accessed February 1, 2007.

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street, Rochester, MN, 55905, USA

    Ravi D. Rao MBBS

Authors
  1. Anjali Bhagra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi D. Rao MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravi D. Rao MBBS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhagra, A., Rao, R.D. Chemotherapy-induced neuropathy. Curr Oncol Rep 9, 290–299 (2007). https://doi.org/10.1007/s11912-007-0036-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0036-x

Keywords

Search

Navigation